Nanjing Sike Pharmaceutical Co., Ltd.   Report issue

For profit Phase 1 Phase 4
Founded: Nanjing China (1935)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2008
NCT00606515
First Marketed Drug
2020
celecoxib (celebrex)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

NANJING

Active Ingredients

Marketed Drugs (1)

celecoxib (celebrex) (2020)

Drugs in Phase 4 Trials (1)

paclitaxel (taxol) (4 trials)

Drugs in Phase 1 Trials (1)

capecitabine (xeloda) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 2